Earnings Call Summary | GeoVax Labs(GOVX.US) Q1 2024 Earnings Conference
Earnings Call Summary | GeoVax Labs(GOVX.US) Q1 2024 Earnings Conference
The following is a summary of the GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript:
以下是GeoVax Labs, Inc.（GOVX）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
GeoVax reported a net loss of $5.9 million for Q1 2024, or $2.47 per share, compared to a loss of $4 million in 2023, or $2.30 per share, primarily driven by the clinical trial programs for CM04S1 and Gedeptin.
Research and development expenses were $4.4 million, up $1.6 million or 57% compared to 2023.
Q1 2024 general and administrative expenses remained relatively unchanged at $1.5 million.
Cash balances at the end of the first quarter stood at $769,000, down $5.7 million from the end of 2023 due to operating activities.
GeoVax報告稱，2024年第一季度淨虧損590萬美元，合每股虧損2.47美元，而2023年虧損400萬美元，合每股虧損2.30美元，這主要是由於 CM04S1 和Gedeptin的臨床試驗計劃推動的。
研發費用爲440萬美元，與2023年相比增長了160萬美元，增長了57％。
2024年第一季度一般和管理費用相對保持不變，爲150萬美元。
由於經營活動，第一季度末的現金餘額爲76.9萬美元，較2023年底下降了570萬美元。
Business Progress:
業務進展：
GeoVax has made significant progress with its two Phase 2 products, Gedeptin and GEO-CM04S1, with the former being in trial phase for cancer patients.
For 2024, GeoVax will continue to focus on Gedeptin and CM04S1, targeting underserved patient populations.
The company expects to report final results for the Gedeptin trial in the first half of 2024.
The company anticipates delivering results from Phase 2 programs for their next-generation COVID-19 vaccine, CM04S1.
There are advanced discussions regarding Project NextGen with BARDA and potential evaluation of Gedeptin as combination therapy with immune checkpoint inhibitors.
CM04S1 is undergoing three Phase 2 trials, two of which are aimed at high-risk populations.
Final results from the vaccine clinical trials are expected in Q4 2024, and the company is planning to raise capital in the near future.
GeoVax在其兩款2期產品Gedeptin和 GEO-CM04S1 方面取得了重大進展，前者正處於癌症患者的試驗階段。
2024年，GeoVax將繼續專注於Gedeptin和 CM04S1，以服務不足的患者群體爲目標。
該公司預計將在2024年上半年公佈Gedeptin試驗的最終結果。
該公司預計其下一代 COVID-19 疫苗 CM04S1 的第二階段計劃將取得成果。
關於BARDA的NextGen項目以及對Gedeptin作爲免疫檢查點抑制劑聯合療法的潛在評估，已經進行了深入的討論。
CM04S1 正在進行三項 2 期試驗，其中兩項針對高風險人群。
疫苗臨床試驗的最終結果預計將在2024年第四季度公佈，該公司計劃在不久的將來籌集資金。
More details: GeoVax Labs IR
更多詳情： GeoVax Labs IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。